| Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor |
|
Mi-kyung Kim, Jeong Hyun Park |
|
Paik Institute for Clinical Research, Department of Internal Medicine, Inje University College of Medicine, Busan, Korea |
| Sodium Glucose Co-Transporter 2 (SGLT2) 억제제 |
|
김미경, 박정현 |
|
인제대학교 의과대학 내과학교실, 백인제기념임상의학연구소 |
Correspondence:
Jeong Hyun Park, Tel: +82-51-890-6074, Fax: +82-51-892-0273, Email: pjhdoc@chol.com
|
|
|
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits
unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
|
| Abstract |
|
Sodium glucose co-transporter 2 (SGLT2) inhibition is a new therapeutic approach for the treatment of type 2 diabetes mellitus,
independent of insulin secretion and activity. SGLT2 inhibitors have a unique mechanism of action via inhibition of renal glucose
reabsorption, which is different from the mechanisms of prior medications. Clinical trials have supported the efficacy of SGLT2 inhibitors
in the reduction of HbA1c as monotherapy or add-on therapy with other existing medications, including insulin. In addition
to their glucose-lowering effect, SGLT2 inhibitors can significantly reduce blood pressure and body weight. The most concerning
side effects are genital and urinary tract infections, especially in females. SGLT2 inhibitors offer a promising potential strategy for
diabetes treatment because they can be combined with nearly any existing anti-diabetic medication, cause less hypoglycemia, and
possess additional metabolic benefits beyond glucose level reduction. |
| Key Words:
Type 2 Diabetes; Renal glucose reabsorption;SGLT2 inhibitors; Urinary tract infection; Genital infection |
|
PDF Links
Full text via DOI
Download Citation
